Clinically, we would expect that surviving patients who are compound heterozygous for deleterious mutations in BRCA1 would have showed an early manifestation of prominent FA features, such as anemia, infection tendency and cancer development [21,22,23]. This evidence concerns the gene BRCA1 and cancer.